Discounts due to biosimilar competition have risen as high as 80% in Europe, according to AbbVie chairman and chief executive officer Richard Gonzalez. Noting that Remicade (infliximab) and Enbrel (etanercept) were the “analogs” that AbbVie had used to plan for the onset of biosimilar competition to its Humira (adalimumab) brand in Europe, he observed that discounting on infliximab and etanercept “ranges from as low as 10% to as high as around 80%”, with “the higher discounting seen in the Nordic tender countries”.
While Gonzalez did not confirm recent rumours that the originator had offered a discount of 80% on the price of...
